Anixa Biosciences is a biotechnology company focused on using the body's immune system to diagnose, treat and prevent cancer. The company's subsidiary, Anixa Diagnostics Corporation, develops Cchek?, a platform for non-invasive blood tests for the early detection of cancer. The company's subsidiary, Certainty Therapeutics, Inc., develops immuno-therapy drugs against cancer. The company has focused on the development of a treatment for ovarian cancer. The company is also engaged in limited patent licensing activities in the area of encrypted audio/video conference calling.

Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The company's product candidates comprised of: NYX 2925, which is a small molecule N-methyl-D-aspartate receptors (NMDAr) modulator being developed for the treatment of chronic pain; NYX-783, which is a small-molecule NMDAr modulator in development for the treatment of post-traumatic stress disorder; NYX-458, which is a small-molecule NMDAr modulator in development for the treatment of Parkinson's disease cognitive impairment; and AGN-241751, which is for the treatment of depressive disorder.

Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company has three platforms: its Oncology Innovation Platform, dedicated to the research and development of its proprietary drugs; its Commercial Platform, focused on the sales and marketing of its specialty drugs and the market development of its proprietary drugs; and its Global Supply Chain Platform, dedicated to providing a supply of active pharmaceutical ingredients for its clinical and commercial efforts. The company's clinical pipeline includes: Orascovery, Src Kinase inhibition, T-cell Receptor-engineered T-cells, and arginine deprivation therapy.

Axsome Therapeutics is a clinical-stage biopharmaceutical company developing therapies for the management of central nervous system (CNS) disorders. The company's CNS product candidates includes: AXS-05, which is for the treatment resistant depression and in agitation associated with Alzheimer's disease; AXS-07, which is initially being developed for the acute treatment of migraine; AXS-09, which is being developed for CNS disorders; AXS-12, which is in development for the treatment of narcolepsy; AXS-02, which is being developed for the treatment of knee osteoarthritis and chronic low back pain; and AXS-06, which is being developed for the treatment of osteoarthritis and rheumatoid arthritis.

AXT is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The company's compound substrates combine indium with phosphorous (indium phosphide: InP) or gallium with arsenic (gallium arsenide: GaAs). InP is a semiconductor substrate used in, among others, fiber optic lasers and detectors, passive optical networks, metro and data center connectivity, silicon photonics, infrared motion control and infrared thermal imaging. The company also makes semi-insulating GaAs substrates used in making semiconductor chips in applications such as power amplifiers for wireless devices, transistors and solar cells for drones. In addition, the company sells certain raw materials.

Ballantyne Strong is a holding company. Through its subsidiaries, the company is focused on serving the cinema, retail, financial, advertising and government markets. The company conducts its operations through three operating segments: Strong Cinema, which provides projection screens, technical support services and other related products to the cinema exhibition industry; Convergent, which delivers digital signage solutions and services to various enterprise markets, including retail, banking and healthcare, as well as certain government agencies and Digital-Out-Of-Home advertising network operators; and Strong Outdoor, which provides advertising services and experiential marketing services.

Barnwell Industries is engaged in the business of: acquiring, developing, producing and selling oil and natural gas in Canada including evaluating proposals by third parties with regard to participation in exploratory and developmental operations elsewhere; investing in land interests in Hawaii; and drilling water and water monitoring wells of varying depths in Hawaii, installing and repairing water pumping systems through its wholly-owned subsidiary, Water Resources International, Inc., which is the distributor for Floway pumps and equipment in the state of Hawaii.

Brainstorm Cell Therapeutics is a biotechnology company engaged in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases including: Amyotrophic Lateral Sclerosis; Progressive Multiple Sclerosis; and Parkinson's disease. NurOwn? technology is based on manufacturing protocol, which induces the differentiation of purified and expanded bone marrow-derived mesenchymal stem cells and consistently generates cells that release multiple neurotrophic factors to modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function.

BroadVision develops, markets, and supports enterprise portal applications that enable companies to unify their e-business infrastructure and conduct interactions and transactions with employees, partners, and customers through a personalized self-service model. The company's offerings consist of a framework for personalization and self-service, modular applications and toolsets that customers use to create e-commerce, portal solutions, and enterprise social networking, and collaboration and knowledge management solutions. The company's primary product offerings are software solutions. The company's solutions include Business Agility Suite, Commerce Agility Suite, Clearvale, Clear, QuickSilver and Vmoso.

Cantel Medical is a provider of infection prevention products and services in the healthcare market. The company has four segments: Medical, which designs, develops, manufactures, sells and installs products and services comprising a circle of infection prevention solutions; Life Sciences, which designs, develops, manufactures, sells, and installs water purification systems; Dental, which designs, manufactures, sells, supplies and distributes infection prevention healthcare products; and Dialysis, which designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers, as well as dialysate concentrates and supplies utilized for renal dialysis

Cassava Sciences is a clinical-stage drug development company. The company focuses on developing new product candidates and to guide these through various regulatory and development pathways in preparation for their potential commercialization. The company's clinical-stage biopharmaceutical assets include: PTI-125, which is its product candidate for the treatment of Alzheimer's disease; and PTI-125Dx, which it is developing as a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company owns worldwide rights to PTI-125 and PTI-125Dx, without royalty obligations to any third party.

cbdMD is a branding and marketing company. Through its CBD Industries LLC subsidiary, the company produces and distributes various cannabidiol (CBD) products, including tinctures, capsules, gummies, bath bombs and topical creams. The company has a line of pet related CBD products under its Paw CBD brand which includes tinctures, treats, and balms. The company's website provides information about CBD quality and existing industry events, as well as United States based customer service. The company tests its hybrid CBD extractions through independent, third-party laboratories. The company's products are available online at www.cbdMD.com and non-affiliated stores.

Century Bancorp is a bank holding company. Through its subsidiary, Century Bank and Trust Company, the company provides services to commercial enterprises, state and local governments and agencies, non-profit organizations and individuals. The company also provides securities brokerage services through a program called Investment Services at Century Bank, which is supported by LPL Financial, a third party securities brokerage business. The company grants single-family and multi-family residential loans, commercial and commercial real estate loans, municipal loans, and a variety of consumer loans. In addition, the company provides savings accounts, NOW accounts, demand deposits, time deposits and money market accounts.

Corporate Office Properties Trust is a real estate investment trust. Corporate Office Properties, L.P. (COPLP) and subsidiaries is the entity through which the company, the sole general partner of COPLP, conducts almost all of its operations and owns almost all of its assets. The company owns, manages, leases, develops and selectively acquires office and data center properties. The majority of the company's portfolio is in locations that support the United States Government and its contractors that engaged in national security, defense and information technology related activities servicing. The company also owns office properties in select urban/urban-like submarkets in the Greater Washington, DC/Baltimore region.

Fastenal is engaged in the wholesale distribution of industrial and construction supplies. The company is a distributor of fasteners and related industrial and construction supplies. This includes threaded fasteners, bolts, nuts, screws, studs, and related washers, as well as miscellaneous supplies and hardware, such as pins, machinery keys, concrete anchors, metal framing systems, wire rope, strut, rivets, and related accessories. The company's fastener product line is primarily sold under the Fastenal product name.

FleetCor Technologies is provider of commercial payment solutions. The company's five primary product lines are Fuel, which provides fuel payment solutions to businesses and government entities who operate vehicle fleets, as well as to main oil companies;Lodging, which provides lodging payment solutions to employees who travel overnight for work purposes; Tolls, which provides an electronic toll and parking payments product; Corporate Payments, which include virtual cards, purchasing cards, travel and entertainment cards; and Gift, which provides gift card product management and processing services. Additionally, the company provides other payment products including fleet maintenance and employee benefits.

Golub Capital BDC is registered as an externally managed, closed-end, non-diversified management investment company. The company makes investments primarily in one stop (a loan that combines characteristics of first lien senior secured loans and second lien or subordinated loans) and other senior secured loans of middle-market companies that are, in most cases, sponsored by private equity firms. The company's investment objective is to generate existing income and capital appreciation by investing primarily in one stop and other senior secured loans of United States middle-market companies.

Good Times Restaurants operates and franchises Bad Daddy's Burger Bar restaurants (Bad Daddy's) and Good Times Burgers & Frozen Custard (Good Times) restaurants. Bad Daddy's and Good Times are two distinctly different, yet complementary, restaurant concepts. Bad Daddy's operates in the casual dining segment of the restaurant industry. Bad Daddy's operates all of its company-owned restaurants under a table service / full-bar service model. The menu is comprised of burgers, salads, sandwiches, and appetizers. Good Times is a quick service restaurant concept offering hand crafted products. Good Times provides a menu of Angus beef and chicken.

La Jolla Pharmaceutical is a biopharmaceutical company focused on the discovery, development and commercialization of therapies for patients suffering from life-threatening diseases. GIAPREZATM (angiotensin II) is approved by the United States Food and Drug Administration as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. LJPC-0118 is the company's investigational product for the treatment of severe malaria. LJPC-401 (synthetic human hepcidin), a clinical-stage investigational product, is being developed for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia and polycythemia vera.

Lovesac is a technology omni-channel company that designs, manufactures and sells furniture comprised of couches called Sactionals and foam beanbag chairs called Sacs. The company markets and sells its products through showrooms and online sales.

Marchex is a call analytics company that helps businesses connect, drive, measure and convert callers into customers. The company's primary product offerings include: Marchex Call Analytics, which is an analytics platform for enterprises; Marchex Display and Video Analytics, which is a product for marketers that buy digital display advertising; Marchex Site Analytics, which is a product for marketers that can drive phone calls from websites; Marchex Social Analytics, which is a product for marketers that buy social media advertising; Marchex Call Marketplace, which is a mobile advertising network for businesses; and Local Leads, which is an advertising solution for small business resellers.

Mirati Therapeutics is a clinical-stage oncology company developing product candidates to address the genetic and immunological promoters of cancer. The company's KRAS inhibitor program is focused on developing inhibitors of KRAS mutations and includes one clinical candidate and a preclinical program. The company also has additional preclinical programs which include product candidates designed to address mutations and tumors where few treatment options exist. The company's clinical and preclinical programs consist of two product candidates: sitravatinib, a multi-kinase inhibitor and MRTX849, a KRAS G12C inhibitor. The company has several discovery programs, including a preclinical program for a KRAS G12D inhibitor.

National Beverage is a holding company. Through its subsidiaries, the company develops, produces, markets and sells a range of sparkling waters, juices, energy drinks and carbonated soft drinks. The company's brands consist of beverages for active and health-conscious consumer (Power+ Brands) including sparkling waters, energy drinks, and juices. The company's portfolio of Power+ Brands includes LaCroix?, LaCroix Curate?, LaCroix NiCola? and Shasta? Sparkling Water products; Rip It? energy drinks and shots; and Everfresh?, Everfresh Premier Varietals? and Mr. Pure? 100% juice and juice-based products. Additionally, the company produces and distributes carbonated soft drinks including Shasta? and Faygo? brands.

On Track Innovations and its subsidiaries are principally engaged in the field of design and development of cashless payment solutions. Co. operates in two segments: Retail and Mass Transit Ticketing; which includes selling and marketing variety of products for cashless payment solutions for the retail market and mass transit ticketing; and Petroleum, which includes manufacturing and selling of fuel payment and management solutions. In addition, certain products for the medical industry and other secure smart card solutions are classified under Other segment. Co. focuses on providing cashless payment solutions based among other things on its contactless near field communications technology.

PBF Energy is a holding company. Through its subsidiaries, the company is engaged as an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the U.S. The company operates in two business segments: refining, which the company produces a variety of products at each of its refineries such as gasoline, ultra-low-sulfur diesel, heating oil, jet fuel, lubricants, petrochemicals and asphalt; and logistics, which through its PBF Logistics LP subsidiary, the company owns or leases, operates, develops and acquires crude oil and refined petroleum products terminals, pipelines, storage facilities and similar logistics assets.

PNC Financial Services Group is a bank holding company. The company has businesses engaged in retail banking, including residential mortgage, corporate and institutional banking and asset management, providing its products and services nationally. The company's segments are: Retail Banking, which provides deposit, lending, brokerage, insurance services, investment management and cash management products and services; Corporate and Institutional Banking, which provides lending, treasury management, and capital markets-related products and services; Asset Management Group, which provides personal wealth management; and BlackRock, which provides a range of investment and technology services.

Safehold is a holding company. Through its subsidiaries, the company operates its business through one segment by acquiring, managing and capitalizing ground leases. Ground leases generally represent the ownership of land underlying commercial real estate properties, which are leased on a long-term basis (base terms are 30 to 99 years, often with tenant renewal options) by the land owner to a tenant that owns and operates the building on top of the land, or what the company refer to as a Safehold?.

Simply Good Foods is a developer, marketer and seller of nutritional foods and snacking products. The company's product portfolio consists primarily of nutrition bars, ready-to-drink shakes, snacks and confectionery products marketed under the Atkins?, SimplyProtein?, and Atkins Endulge? brand names. The Atkins brand approach focuses on a healthy eating approach with reduced levels of refined carbohydrates and sugars and encourages the consumption of lean protein, fiber, fruits, vegetables and healthy fats. Through third-party partnerships, the company provides complementary Atkins branded frozen meals.

Syros Pharmaceuticals is a biopharmaceutical company engaged in the non-coding regulatory region of the genome to develop a new wave of medicines that control the expression of genes. The company's primary product candidates are: SY-1425, a selective retinoic acid receptor alpha agonist that is used to treat acute myeloid leukemia patients; SY-1365, a selective inhibitor of cyclin-dependent kinase 7 (CDK7), that is being evaluated in a Phase 1 clinical trial in patients with advanced solid tumors; and SY-5609, a CDK7 inhibitor that can be administered orally, which is being evaluated in investigational new drug application, enabling preclinical studies.

Taylor Devices is engaged in the design, development, manufacture and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment and structures. These products include: Seismic Dampers, which mitigate the effects of earthquake tremors on structures; Fluidicshoks?, which are shock absorbers for use in the defense, aerospace and commercial industry; Crane and Industrial Buffers, which used for industrial application on cranes, ships, container ships, railroad cars, truck docks, ladle and ingot cars, ore trolleys and car stops; and Self-Adjusting Shock Absorbers, which are designed for high cycle application in heavy industry.

vTv Therapeutics is a holding company. Through its subsidiaries, the company is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates. The company's drug candidate for the treatment of Alzheimer's disease, azeliragon (TTP488), is an orally administered small molecule antagonist targeting the receptor for advanced glycation endproducts. The company's type 2 diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor. The company is also developing TTP399 for type 1 diabetes.